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Background: We have previously demonstrated an aberrant overexpression of the microtubule-associated protein
TPX2 in colon cancer using a genome-wide gene expression profiling analysis. Here, we aim to investigate its
expression pattern, clinical significance, and biological function in colon cancer.
Methods: TPX2 expression was analyzed in human colon cancer cell lines and tumor samples. The effect of TPX2
on cell proliferation, tumorigenesis, and metastasis was examined in vitro and in vivo.
Results: TPX2 was overexpressed in 129 of the 203 (60.8%) colon cancer metastatic lesions, with the expression
being significantly higher than that in primary cancerous tissue and normal colon mucosa. Overexpression of TPX2
was significantly associated with clinical staging, vessel invasion, and metastasis. In survival analyses, patients with
TPX2 overexpression had worse overall survival and metastasis free survival, suggesting that deregulation of TPX2
may contribute to the metastasis of colon cancer. Consistent with this, suppression of TPX2 expression inhibited
proliferation and tumorigenicity of colon cancer cells both in vitro and in vivo. Strikingly, we found that TPX2
knockdown significantly attenuated the migration and invasion ability of colon cancer cells, which was further
shown to be mechanistically associated with AKT-mediated MMP2 activity.
Conclusions: These findings suggest that TPX2 plays an important role in promoting tumorigenesis and metastasis
of human colon cancer, and may represent a novel prognostic biomarker and therapeutic target for the disease.
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Colorectal cancer is one of the leading causes of cancer-
related deaths worldwide [1]. Approximately 50–60% of
patients diagnosed with colorectal cancer develop colo-
rectal metastases, and 80–90% of these patients have
unresectable metastatic live disease [2-5]. However, the
precise genetic changes responsible for the initiation and
progression of colon cancer remain poorly understood.
Therefore, there is a need to identify new gene targets
and develop novel target-specific therapies.
TPX2, a microtubule-associated protein, is encoded by a
gene located on human chromosome band 20q11.1 [6,7].
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stated.mammalian cells, which is mediated through binding of
the COOH-terminal domain of Xenopus kinesin-like pro-
tein 2 (Xklp2) to microtubules [8,9]. TPX2 is downstream
of Ran-GTP and plays a central role in spindle formation.
In the early stages of mitosis, TPX2 is released in a
RanGTP-dependent manner [10,11], and interacts with
Aurora A kinase. This results in the localization of Aurora
A to the microtubules of the mitotic spindle, which then
initiates spindle assembly [12]. The N-terminal domain of
TPX2 interacts with Aurora A, thus protecting Thr288 in
the T-loop of the kinase from dephosphorylation by Phos-
phatase Protein 1 [13]. Cells deficient in the Aurora A/
TPX2 complex present short spindles, which results in
mitotic failure [14]. TPX2 expression is tightly regulated
during the stages of cell cycle, becoming detectable at the
G1-S transit and disappearing at the completion of cyto-
kinesis [15]. Therefore, TPX2 expression might provide a
more precise evaluation of the proliferative behavior of
tumor cells.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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errant expression of TPX2, such as copy number-driven
overexpression from the amplicon on 20q11.2 in non-
small-cell lung cancer [16], high mRNA and protein
levels in pancreatic ductal adenocarcinomas [17], and in
more than 50% of patients of giant-cell tumor of the
bone [18]. However, no attempt has been made to inves-
tigate the expression of TPX2 in human colon cancer. In
this study, we investigate the expression of TPX2 at the
mRNA and protein level in human colon cancer, clarify
the correlation between the TPX2 expression and clini-
copathological parameters, and predict the underlying
mechanism of its potential role in the proliferation and
metastasis of colon cancer cells.
Material and methods
Patient information and tissue specimens
This study was approved by the Institutional Research
Ethics Committee and written consents were obtained
from all 203 patients with pathologically and clinically
confirmed colon cancer. None of the patients had received
radiotherapy or chemotherapy before surgery. Staging was
based on pathological findings according to the American
Joint Committee on Cancer (AJCC). Based on the tumor
(T), node (N), and metastasis (M) classification system, we
identified 24 cases at stage I, 81 at stage II, 80 at stage III,
and 18 at stage IV. The matching adjacent noncancerous
tissue, primary colon cancer tissue, and lymph node me-
tastasis lesions from the 203 patients was fixed in formalin
and embedded in paraffin for histological analysis and im-
munohistochemical studies. Fresh samples were dissected
manually to remove connective tissues and were immedi-
ately stored in liquid nitrogen until western blot analysis.
TMA construction and immunohistochemistry
The tissue array construction procedure has been described
previously [19]. Sections (4-μm thick) of TMA slides were
prepared and processed for immunostaining. The paraffin
sections were de-paraffinized in xylene and rehydrated in a
graded alcohol series, boiled with 10 mmol/L of citrate buf-
fer (pH 6) for 10 min, and treated with 0.3% H2O2 for
10 min. The steps were performed using the Envision two-
step method. The Envision and DAB Color Kit was pur-
chased from Gene Tech Company Limited (Shanghai). The
TPX2 anti-human rabbit polyclonal antibody was used at a
dilution of 1:200, PBS was used as a negative control. Im-
munoreactivity was evaluated independently by two re-
searchers in a blinded fashion. The evaluation was based
on the staining intensity and extent of staining. The stain-
ing intensity was graded as follows, 0: no staining, 1+: mild
staining, 2+: moderate staining, and 3+: intense staining.
The staining area was scored using the following scale, 0:
no staining of cells, 1+: <10% of tissue stained positive, 2+:
10–50% stained positive, and 3+: >50% stained positive.The sum of staining score (intensity + extension) index was
designated as follows, 0–2: negative expression, 3–4: weak
expression, and 5–6: strong expression.
RNA extraction, reverse transcription (RT), and
quantitative real-time PCR (qPCR)
RNA was isolated according to the manufacturer’s instruc-
tions (TRIzol, Invitrogen, USA). One microgram of total
RNA from each sample was subjected to first-strand cDNA
synthesis according to the manufacturer’s recommen-
dations (Promega, USA). Quantitative PCR was performed
on a Mastercycler® eprealplex (Eppendorf) with an IQTM
SYBR Green Supermix Kit (BIO-RAD) according to the
manufacturer’s protocol. TPX2 was amplified with the
following primers: 5′-AGGGGCCCTTTGAACTCTTA-3′
(forward primer) and 5′-TGCTCTAAACAAGCCCCATT-
3′ (reverse primer). GAPDH was used as an endogenous
control with the following primers: 5′-CGGATTTGGTCG
TATTGG-3′ (forward primer) and 5′-TCCTGGAAGAT
GGTGATG-3′ (reverse primer). The cycling conditions for
TPX2 and GAPDH were as follows: one cycle at 95°C for
3 min; 40 cycles of 95°C for 15 s, and 60°C for 60 s. The
specificity of the PCR amplification was validated by the
presence of a single peak in the melting curve analyses.
Each RT-qPCR experiment was repeated three times.
Plasmids
For depletion of TPX2, a human siRNA sequence was
cloned into the pSilencer™ 2.1-U6 puro Vector (Ambion)
according to manufacturer’s protocol. The target sequence
was 5′-AAGAATGGAACTGGAGGGCTT-3′. A scram-
bled siRNA (5′-GTACCGCACGTCATTCGTATC -3′)
with no homology to the mammalian mRNA sequences
was used as a negative control. Transfection of TPX2-
shRNA or control-shRNA plasmid was performed using




Cells were seeded in 96-well plates at an initial density of
0.2 × 104 cells/well. At each time point, cells were stained
with 100 μL sterile MTT dye (0.5 mg/mL, Sigma) for 4 h
at 37°C, followed by removal of the culture medium and
addition of 150 μL of dimethyl sulphoxide (DMSO)
(Sigma, St. Louis, MO, USA). The absorbance was mea-
sured at 570 nm, with 655 nm as the reference wave-
length. All experiments were performed in triplicate.
Cell migration and invasion assays
Cell migration and invasion assays were conducted using
a modified 24-well Boyden chamber with a membrane
that was uncoated, or coated with Matrigel (BD Biosci-
ences). Briefly, 24 h after transfection of both HCT116
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shRNA) or TPX2 shRNA, the cells were harvested and re-
suspended in DMEM at a concentration of 5 × 104 cells/
mL. Cells prepared in 500 uL of DMEM were loaded in
the upper wells, and a medium containing 20% FBS was
placed in the lower wells as a chemoattractant stimulus.
Cells that had migrated to the bottom surface of the filter
were fixed, stained with H&E, and counted under a micro-
scope in three randomly selected fields at a magnification
of 200 × .
Gelatin zymography assay
SW620 cells (2 × 105 cells) were seeded in six-well plates
and incubated overnight at 37°C. The cells were washed
twice with Hanks’ balanced salt solution and cultured for
an additional 24 h in serum-free medium. Culture superna-
tants were collected for collagenase activity assays. Culture
supernatants (40 μL) were resolved on a 7.5% sodium do-
decyl sulfate polyacrylamide gel that contained 1 mg/mL
gelatin (Sigma Chemical Co., St. Louis, MO). The gel was
washed for 30 min at room temperature in wash buffer
(50.0 mM Tris–HCl [pH 7.5], 15.0 mM CaCl2, 1.0 μM
ZnCl2, and 2.5% Triton X-100) and then incubated for 24 h
at 37°C in the same buffer at a final concentration of 1%.
The gel was then stained with 0.1% Coomassie Brilliant
Blue R-250; clear zones against the blue background indi-
cated the presence of gelatinolytic (i.e., collagenase) activity.
Soft agar assay
Cells were suspended in 0.3% agar medium (DMEM con-
taining 10% FBS) and then plated on a 0.6% agar base layer
at a concentration of 1 × 103 cells per six-well plate. TheFigure 1 Analysis of TPX2 expression in colon cancer cell lines and tis
performed to examine TPX2 expression in colon cancer cell lines. (B) Real-t
examine TPX2 expression in eight cases of primary colon carcinomas (T) ancells were incubated in a humidified atmosphere (5% CO2)
at 37°C for 10 days, following which the number of col-
onies that were 50-μm or larger were counted.
Xenografted tumor model
SW620 cancer cells with stably silenced TPX2 (sh-TPX2)
or control (sh-Control and mock) (1 × 106 cells) were sub-
cutaneously injected into the flanks of BALB/c-nu mice as
previously described [20]. All procedures involving mice
were conducted in accordance with Fudan University
Shanghai Cancer Center Animal Care guidelines. All ef-
forts were made to minimize animal suffering, to reduce
the number of animals used, and to utilize possible alter-
natives to in vivo techniques.
Statistics
ANOVA test was used to determine the statistical sig-
nificance of differences between experimental groups.
The Kaplan-Meier method was used to analyze colon
cancer patients’ cumulative survival rate. A Cox propor-
tional hazards model was used to calculate univariate
and multivariate hazard ratios for the study variables.
SPSS software 13.0 (SPSS, Chicago, IL, USA) was used
for the analyses. A P value of 0.05 was considered as sta-
tistically significant.
Results
Aberrant overexpression of TPX2 in colon cancer tissue
and cell lines
Real-time PCR analyses revealed that mRNA expression
level of TPX2 was markedly higher in all colon cancer cell
lines than in non-malignant human NCM460 colonic cellsues. (A) Real-time PCR (A1) and western blotting (A2) analysis were
ime PCR (B1) and western blotting (B2) analysis were performed to
d paired non-cancerous adjacent tissues (N).
Table 1 Correlation between TPX2 expression and
clinicopathologic characteristics
Cases TPX2 protein expression(n) P-value
Negative Weak Strong
Age
<65 81 33 23 25 0.435
≥65 122 46 28 48
Gender
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TPX2 was also higher in the colon cancer cell lines but not
so markedly as its mRNA expression level (Figure 1A2).
Furthermore, comparative analysis showed that the mRNA
and protein levels of TPX2 were differentially upregulated
in all 4 colon cancer samples compared to the matched ad-
jacent non-tumor tissues (Figure 1B1, B2), suggesting that
TPX2 expression is upregulated in colon cancer. The clini-
copathologic characteristics of four patients used in west-
ern Blot and RT-PCR analysis was provided in the
(Additional file 1: Table S1).
Association between TPX2 expression and the clinical
features of colon cancer
To determine whether TPX2 clinically correlated with
colon cancer progression, the expression of TPX2 was de-
termined by immunohistochemistry in a tissue microarray
containing 203 cases of primary colon cancer paired withFigure 2 TPX2 expression and pathologic features in colon cancer
specimens. (A) Immunohistochemical staining of TPX2 in TMA. TPX2
was localized within the nuclei. Elevated TPX2 expression in the tumor
cells of colon cancer tissue (A2, A3, and A4) compared to adjacent
normal mucosa with negative staining (A1) (original magnification:
400X for the inserts, 100X for all). (B) The metastasis-free survival (MFS)
and overall survival (OS) rates were estimated by the Kaplan–Meier
method. Both the MFS rate and OS rate of patients with TPX2 positive
primary tumor were significantly lower than that of patients with TPX2
negative primary tumor (log-rank test, P < 0.001).their non-cancerous tissue and 66 lymph node metastases
(LNM). We found that TPX2 was dramatically upregu-
lated in primary colon cancer (61.1%), but it was either
only detected minimally, or not at all (98%) in adjacent
normal colonic tissue. The representative expression pat-
tern in both tumor and non-tumor samples are shown in
Figure 2A. The quantitative analysis of IHC staining isMale 86 33 23 30 0.898
Female 117 46 28 43
Location
Right 84 31 25 28 0.632
Transverse 19 6 6 7
Left 20 7 6 7
Sigmoid 80 36 14 31
Stage
I 24 15 6 3 0.004
II 81 38 20 23
III 80 23 21 36
IV 18 3 4 11
T stage
T1 8 4 2 2 0.008
T2 23 13 6 4
T3 76 38 17 21
T4 96 24 26 46
N stage
N0 108 55 27 26 0.001
N1 61 18 13 30
N2 34 6 11 17
Metastasis
M0 185 76 47 62 0.048
M1 18 3 4 11
Vessel invasion
No 189 74 49 66 0.457
Yes 14 5 2 7
Differentiation
Well 99 44 26 29 0.108
Moderate 74 27 14 33
Poor 30 8 11 11
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levels of TPX2 were closely correlated with the T classifi-
cation (P = 0.008), lymph node involvement (P = 0.001),
distant metastasis (P = 0.048), and clinical stage (P = 0.004)
in colon cancer patients. Collectively, these data indicate
that TPX2 may be involved in colon cancer carcinogenesis
and metastasis.TPX2 expression is significantly associated with lymph
node metastasis and poor survival in colon cancer
patients
Furthermore, we postoperatively analyzed the predictive
significance of TPX2 in the development of distant me-
tastasis. The metastasis-free survival (MFS) time was
analyzed in 185 patients in stages I-III, who accepted
radical colectomy. The proportion of patients who de-
veloped metastasis from primary colon cancer after
radical colectomy differed substantially between the TPX2-
positive and TPX2-negative group (Figure 2B, left).
The risk of developing distant metastases after radical
colectomy was much higher in patients with a TPX2-
positive tumor relative to patients with a TPX2-negative
tumor (P < 0.001) (TPX2-positive, 40 [36.7%] of 109
patients, mean follow-up 64.5 months [range 58.4-70.6];
TPX2-negative, 8 [10.5%] of 76, 81.2 [77.3-85.1]). Based
on these results, TPX2 could serve as a novel prognostic
marker to predict risk of distant metastases in patients
with radical colectomy (Hazard Ratio, 4.3; [95% CI 2.0-9.2];
P < 0.001).
A Kaplan-Meier analysis of the data also indicated that
the expression of TPX2 was significantly correlated with
the overall survival (OS) of colon cancer patients (log-rank
test, P < 0.001, Figure 2B, right). Patients with TPX2-
positive tumors had a significantly lower 5-year OS than
those with TPX2-negative tumors (56.4% vs. 80.6%, HR
3.0 [95% CI 1.7-5.2]. In a multivariate analysis examining
clinicopathologic variables such as clinical stage, differen-
tiation grade, and venous invasion, the expression of
TPX2 had an independent prognostic value to predict pa-
tient outcome, including both the OS and the metastasis-




AJCC stage (I/II vs. III/IV) <0.001 3.7
Histologically poorer grade † 0.256 1.6
Vessel invasion (no vs. yes) 0.022 2.9
TPX2 (negative vs. positive) 0.001 3.7
N.S., Not significant; HR, Hazard ratio; CI, Confidence interval; † “Histologically poore
adenocarcinoma, and poorly differentiated adenocarcinoma.Downregulation of TPX2 inhibits proliferation of colon
cancer cells in vitro and in vivo
The impact of TPX2 on proliferation of colon cancer
cells was evaluated by knockdown of TPX2. The MTT
assay showed that depletion of TPX2 expression caused
a marked reduction in the viability of HCT116 and
SW620 cells (Figure 3A and B). These results demon-
strate that TPX2 suppression could inhibit the prolifera-
tion ability of colon cancer cells.
Since TPX2 was correlated with the clinical characteris-
tics of colon cancer, we further investigated the effect of
TPX2 on the tumorigenic activity of colon cancer cell lines.
Control cells (MOCK and shRNA) and SW620-TPX2-
shRNA cells were subcutaneously injected into nude mouse
(n = 5/group). As shown in Figure 3C and D, the tumors
formed from SW620-TPX2-shRNA cells grew much more
slowly than those from the control cells. After 4 weeks, the
weight of tumors induced by the TPX2-suppressed cells
was significantly reduced when compared to that induced
by control cells (Figure 3E). Furthermore, IHC-stained sec-
tions of mouse tumors that demonstrated a high level of
TPX2 also strongly stained for Ki67 (Figure 3F), consistent
with the cell proliferation results in vitro. Together, our re-
sults indicated that TPX2 plays a critical role in the tumori-
genicity of colon cancer cell lines both in vitro and in vivo.
Gene Silencing of TPX2 expression in colon cancer cells
leads to Akt reduction
As TPX2 expression is linked to poor survival of colon
cancer patients, we wanted to further explore the molecu-
lar mechanism of its action. We found that the phosphor-
ylation and activation of Akt was markedly reduced in
shRNA-TPX2 transfected cells compared with the control
group, while downregulation of TPX2 did not affect ERK-
1/2 activation, which are involved in a different pathway
from Akt (Figure 4A). Furthermore, knocking down TPX2
in SW620 reduced nuclear Akt (Figure 4E).
To confirm whether TPX2 induced proliferation of
colon cancer cells through the Akt pathway, we overex-
pressed TPX2 in SW480, which is a lower grade colon
cancer cell line, then treated with a phosphoinositide
3-kinase (PI3K) inhibitor LY294002. Blockade of Akt) and overall survival (OS) of 203 colon cancer patients
FS) Multivariate analysis (OS)
CI (95%) p value HR CI (95%)
1.8-7.5 <0.001 4.6 2.5-8.4
0.7-3.7 <0.001 3.0 1.7-5.3
1.1-7.4 0.176 1.5 0.8-3.1
1.7-8.1 0.006 2.2 1.2-3.9
r grade” corresponded to signet ring cell carcinoma, mucinous
Figure 3 TPX2 inhibition suppresses proliferation of colon cancer cells in vitro and in vivo. (A) HCT116 (left) and SW620 (right) cells were
treated with shRNA-TPX2 or control shRNA (control) or Oligofectamine alone (mock) for 48 h, following which cells were harvested for analysis
of TPX2 expression by western blot. (B) HCT116 (left) and SW620 (right) cells growth curve measured by a 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) assay. Each point indicates the mean of the spectrometric absorbance ± S.D. of three independent
experiments (P < 0.001). SW620 cells with shRNA-TPX2, shRNA (control) or Mock were injected subcutaneously into the right scapular region
of nude mice. Gross tumors in the mice are shown (C); tumors were measured (D) and weighted (E), (F) Representative Photographs of Ki67
staining in paraffin sections from tumors injected with shRNA-TPX2, or control cells (magnification: 100X).
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in SW480 cells, as determined by a colony formation
assay and MTT assay (Figure 4B, C and D). Together,
these data suggest that downregulation of TPX2 in-
hibits Akt activation, and Akt activation is an import-
ant step in the TPX2-induced proliferation of colon
cancer cells.Gene silencing of TPX2 suppresses the migratory and
invasive ability of colon cancer cells through a
modulation of MMP2 expression and activity
As TPX2 is linked to the advanced clinical stage and
poorer MFS of colon cancer patients, we then wanted to
determine the possible role of TPX2 on cell migration and
invasion activity in vitro. The effect of TPX2 knockdown
Figure 4 Inhibition of p-Akt by TPX2 gene silencing in colon cancer cells. (A) The expression of p-Akt, total Akt, p-ERK-1/2, and ERK-1/2 on
SW620 cells treated with shRNA-TPX2, shRNA (control), or Oligofectamine alone (Mock) was analyzed by western blotting. Blocking Akt activation
decreases the colony formation induced by TPX2. SW480 cells were transfected with pcDNA3.1 or pcDNA3.1-TPX2 and then treated with
LY294002 (25 μmol/L) for 2 h. (B) p-Akt and total Akt was analyzed by western blotting. (C) The colony formation ability of the cells was
determined by a colony formation assay. The bars indicate mean colony numbers from a representative experiment done in triplicate; with
SD. P < 0.05 compared to the no-treatment group. (D) Cell growth curve was measured by a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay. Each point indicates the mean of the spectrometric absorbance ± S.D. of three independent experiments (P < 0.01)
(E) Immunofluorescence microscopic analyses of Akt activation. SW620 cells were infected with shRNA-TPX2 or control cells (control shRNA
and mock). Then, the cells were immunostained for Akt (green) and their nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; blue).
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migration chambers. Compared to the control groups,
TPX2 silencing resulted in significantly reduced migratoryability (P <0.01, Figure 5A and B). We also assessed the
effect of TPX2 depletion on tumor invasion and demon-
strated that disruption of endogenous TPX2 expression
Figure 5 TPX2 inhibition suppressed invasion and migration of colon cancer cells. (A) Representative images show migration and invasion
of HCT116 and SW620 cells infected with shRNA-TPX2, shRNA (control), or Oligofectamine alone (mock) in a transwell assay (200×). (B) Data are
presented as mean relative numbers of migrated cells from 4 fields (*P < 0.01, versus mock group).
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(Figure 5A and B). The results indicate a critical role of
TPX2 in the metastasis of colon cancer.
To better understand the role of TPX2 in the progres-
sion and metastasis of colon cancer cells, we explored the
possible roles of metastasis-related molecules downstream
of TPX2. We found that knockdown of endogenous TPX2
led to substantial reduction in both mRNA and protein
level of MMP2 (Figure 6A, B, and D). We next examined
the potential effect of TPX2 on the activity of MMP2
using zymography analysis. Higher activity of MMP2 was
observed in control group compared to ShRNA-TPX2
treated cells (Figure 6C). The data suggest that TXP2 may
be a potential target in colon cancer therapy due to itsability to modulate downstream MMP2 expression and
activity.
Discussion
The motor-binding targeting protein for Xklp2 (TPX2)
is the first cell cycle- associated protein with a restricted
pattern of expression and high level of activity found in
several malignant tumors [21,22]. Aberrant expression of
TPX2 has been associated with both malignant trans-
formation of respiratory epithelium and progression of
squamous cell lung cancer [23,24]. It has been shown
that the TPX2 gene is amplified in pancreatic tumor tis-
sues and may serve as biomarker for identifying subpop-
ulations of patients sensitive to Aurora-A inhibitor
Figure 6 Gene silencing of TPX2 expression in colon cancer cells suppresses MMP-2 activity. The expression or enzyme activity of TPX2
on SW620 cells treated with shRNA-TPX2, shRNA (control), or Oligofectamine alone (mock) was analyzed by RT-PCR (A), western blot (B), and
zymography assay (C). (D) Immunofluorescence microscopic analyses of MMP-2. SW620 cells were infected with shRNA-TPX2 or control cells
(control shRNA and mock). The cells were then immunostained for TPX2 (green) and MMP-2 (red), their nuclei were stained with 4′,6-diamidino-2-
phenylindole (DAPI; blue).
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ever, little work has been done to explore the role of
TPX2 in colon cancer.
This study has shown for the first time that aberrant
expression of TPX2 is significantly associated with un-
favorable clinicopathologic variables of colon cancer and
that overexpression of TPX2 leads to the activation of
Akt, a mechanism by which TPX2 promotes prolifera-
tion and tumorigenesis. The study also shows that TPX2
plays a critical role in the progression and metastasis of
colon cancer, which could be mechanistically associated
with activity of MMP2 and finally, that TPX2 protein ex-
pression could serve as a novel biomarker to predict therisk of metastasis in colon carcinoma patients after a
colectomy.
Tumorigenesis, characterized by uncontrolled cell growth
and tumor formation is associated with alterations in
genes or proteins related to regulation of proliferation, cell
death, and genomic stability [27,28]. Thus, identification
of genes and their products involved in the molecular
events leading to tumorigenesis is critical to developing ef-
fective therapeutic strategies. In our study, we found that
TPX2 was a potential marker involved in tumorgenesis of
colon cancer. TPX2 was markedly upregulated in colon
cancer cells and tissues. Moreover, silencing of TPX2
reduced the tumorigenicity of colon cancer cells both
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protein in the development and progression of colon can-
cer. Here we report further that decreased expression of
TPX2 in colon cancer cell line SW620 caused a significant
decrease in the level of p-Akt, which is an important
signaling pathway for tumor formation. Moreover, the
PI-3 K-specific inhibitors LY294002 can inhibit TPX2-
induced colony formation in vitro. Therefore, TPX2 may
cause proliferation of colon cancer cells through an activa-
tion of the PI3K/Akt signaling pathway, a potential thera-
peutic target.
In addition to playing a critical role in cancer cell pro-
liferation and tumorigenesis, TPX2 appears to be in-
volved in metastasis, as it is tightly cell-cycle regulated
[29,30]. Our study observed that TPX2 expression was
closely associated with tumor stage and lymph node me-
tastasis in colon cancer, suggesting that TPX2 could be
important in colon cancer progression. Invasion and me-
tastasis are characteristic features of colon cancer and
the main factors related to the poor prognosis in pa-
tients with colon cancer [31]. Thus, the identification of
the molecular mechanisms responsible for the control of
the invasive and metastatic potential of colon cancer is
crucial to inhibit these processes. In the present study,
we explored whether TPX2 contributed to migration
and invasion of colon cancer cells in vitro. Our data re-
vealed that depletion of TPX2 could suppress colon can-
cer cell migration and invasion in vitro. These results
suggest that TPX2 plays an important role in invasion
and metastasis of colon cancer and that TPX2 may be a
new and crucial therapeutic target for colon cancer.
The degradation of ECM is a critical step in tumor inva-
sion and metastasis. Matrix metalloproteases (MMPs), a
family of zinc-dependent endopeptidases, play a major
role in the degradation of ECM components [32,33].
Among these MMPs, matrix metalloproteinase-2 (MMP2)
has been considered critical for cancer invasion and me-
tastasis [34,35]. Here we found that downregulation of
TPX2 could diminish the expression of MMP2, both at
the mRNA and protein levels. It has been reported that
the phosphatidylinositol 3-kinase/Akt signaling pathway
plays a critical role in promoting MMP-2 expression
[36,37]. Therefore, these results suggest that the downreg-
ulation of TPX2 could potentially inhibit the tumorigen-
esis and metastasis of colon cancer, partially through
PI3K/Akt pathway and MMP-2.
Conclusion
In summary, we show here for the first time that TPX2 is
highly expressed in colon cancer tissues and cell lines. In-
hibition of TPX2 expression inactivates the PI3K/Akt
signaling pathway and reduces tumorigenicity of colon
cancer cells. It also results in the downregulation of
MMP2, resulting in reduced metastasis. These resultssuggest that TPX2 expression is critical for the progres-
sion and invasiveness of colon cancer. Since TPX2 has
multiple roles in the progression of colon cancer, including
regulation of proliferation, invasion, and metastasis of
colon cancer cells, the frequent upregulation of TPX2 in
human colon cancers highlights its importance as a novel
therapeutic target in the treatment of colon cancer.
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